Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grapiprant - AskAt

Next Previous
X
Search
Drug Profile

Grapiprant - AskAt

Alternative Names: 423; AAT-007; ARY 007; CJ-023; CJ-023,423; CJ-23423; IK 007; MR-10A7; RMX-1002; RQ-00000007; RQ-07; RQ-7

Latest Information Update: 24 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AskAt; HaiHe Biopharma; Ikena Oncology; M. D. Anderson Cancer Center; Ningbo NewBay Medical Technology; Pfizer
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cancer pain; Neuropathic pain
  • Phase II Pain
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Colorectal cancer; Hypersensitivity; Inflammation

Most Recent Events

  • 20 Mar 2024 Ikena Oncology terminates its licence for Grapiprant in Worldwide (except China)
  • 15 Feb 2024 Ikena Oncology and AskAt has patents pending for EP4 antagonists in the US
  • 11 Sep 2023 Grapiprant is still in phase I trial for Solid tumours (Late-stage disease) in China (PO, Tablet) (RaQualia Pharma pipeline, September 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top